The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?

<div>AR and AR-V7 gene and protein. The schematic indicates (a) the structural organisation of the AR gene and protein (NTD: amino terminal domain; DBD: DNA-binding domain; LBD: ligand-binding domain). (b) The transcription and translation of the AR-V7 protein including the exon/intron composition of the AR, highlighting the cryptic exon CE3 (middle) and domains of the AR retained in the AR-V7 protein (bottom).</div>

Prostate Cancer

fig2

Figure 2

Figure 2: The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player? 

Figure 2 | The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player? 